Flu & Viruses
-
UK trial to prevent post-discharge COVID relapse
A clinical trial is being launched in the UK to reduce the number of people who die in the months following a hospital treatment for COVID-19. Read more
-
TB testing slumped during pandemic
Testing for tuberculosis (TB) plummeted by almost half in 2020 because of the COVID-19 pandemic, new analysis has revealed. Read more
-
COVID vaccine approval grows significantly
Confidence in COVID-19 vaccination in the UK has grown substantially this year, according to a new survey. Read more
-
COVID-19 associated with hearing loss
Hearing loss and auditory and vestibular problems have been linked to COVID-19 after-effects, according to a new study. Read more
-
Government COVID-19 taskforces need more women
Women’s absence from COVID-19 government taskforces around the globe perpetuates the gender divide and will hamper their recovery from the pandemic, according to a new United Nations report. Read more
-
COVID-19 vaccines may protect against variants
Existing COVID-19 vaccines are likely to protect against the Brazilian coronavirus variant, scientists at the University of Oxford, UK, have reported. Read more
-
Vaccine linked to rare VTE events – but safe overall, regulators say
Two very rare kinds of venous thromboembolism have affected a small number of people under the age of 50 after COVID-19 vaccination, regulators reported yesterday. Read more
-
COVID-19 machine learning models ‘unusable’
Machine learning models for diagnosing COVID-19 are not suitable for clinical use because of biases, methodological flaws, lack of reproducibility and “Frankenstein datasets”, researchers warned last night. Read more
-
Global review determines COVID-19 risks to pregnant women
Pregnant women – particularly those from ethnic minority backgrounds – have been at increased risk of severe COVID-19 and more likely to need intensive care or invasive ventilation than non-pregnant women with the virus, researchers report today. Read more
-
COVID-19 gout treatment trial to include under-50s
A UK COVID-19 trial that is assessing the effectiveness of a common gout drug to help alleviate the virus’s symptoms can now include under-50s, it has been announced. Read more